Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer (Q34557318)

3 August 2017

title

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer (English)

1 reference

3 August 2017

1 reference

Lynne Bemis

6

0 references

Angelo Sidoni

Angelo Sidoni

15

0 references

Federico Cappuzzo

Federico Cappuzzo

1

0 references

Claudio Doglioni

Claudio Doglioni

14

0 references

Marileila Varella-Garcia

20

Marileila Varella-Garcia

1 reference

3 August 2017

2

Fred R Hirsch

1 reference

3 August 2017

17

Wilbur A Franklin

1 reference

3 August 2017

19

Paul A Bunn

1 reference

3 August 2017

Elisa Rossi

3

1 reference

3 August 2017

Stefania Bartolini

4

1 reference

3 August 2017

Giovanni L Ceresoli

5

1 reference

3 August 2017

Jerry Haney

7

1 reference

3 August 2017

Samir Witta

8

1 reference

3 August 2017

Kathleen Danenberg

9

1 reference

3 August 2017

Irene Domenichini

10

1 reference

3 August 2017

Vienna Ludovini

11

1 reference

3 August 2017

Elisabetta Magrini

12

1 reference

3 August 2017

Vanesa Gregorc

13

1 reference

3 August 2017

Maurizio Tonato

16

1 reference

3 August 2017

Lucio Crino

18

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Journal of the National Cancer Institute

3 August 2017

published in

1 reference

3 August 2017

volume

97

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

643-655

1 reference

Global cancer statistics in the year 2000.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Tyrosine kinase inhibition: an approach to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Tyrosine kinase inhibitors in preclinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

A chemical mismatch cleavage method useful for the detection of point mutations in the p53 gene in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

'Touchdown' PCR to circumvent spurious priming during gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJI112

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJI112

1 reference

3 August 2017

1 reference